Demis Hassabis-founded Isomorphic Labs completes $5 billion Series C funding round
Isomorphic Labs has completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and funding from Alphabet as well. The funds will be used to design and develop new drugs with AI, advancing foundational biology models, disease understanding, and the first batch of therapeutic programs into clinical trials. This round comes about three and a half months after Hassabis stepped down as CEO of Google DeepMind; the company's previous round was a $2.1 billion Series B in May; according to Dealroom, drug discovery startups raised a cumulative $23.2 billion in 2026, setting a record.
Why read this
AI score 52
Beyond the funding size and investor structure, the original text also provides record data showing that drug discovery startups raised a cumulative $2.32 billion in 2026, which can serve as a reference for gauging the heat of capital in AI pharma.
Topics
Body
Isomorphic Labs, an artificial intelligence drug discovery startup founded by former Google DeepMind chief Demis Hassabis, has raised a $5 billion Series C, the company said on Tuesday.
Isomorphic's round comes three-and-a-half months after Hassabis stepped back as CEO of DeepMind, Google's AI lab, which he co-founded before the Big Tech giant acquired it in 2014.
The round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz, with investment from Alphabet, Google's parent. The fresh funds will help fund the design and development of new medicines using AI.
Drug discovery startups have seen record funding poured into them by investors in 2026 as companies look to capitalize on advances in AI. OpenAI and Anthropic have also been investing in tools to develop new medicines using the technology.
Hassabis has been CEO of Isomorphic Labs since the startup spun out of DeepMind in 2021.
"When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," said Hassabis.
"This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients," he added.
Isomorphic is building a proprietary drug design engine and therapeutic candidate pipeline designed with AI, which it says will help it deliver the next generation of medicines.
Anthropic announced it was launching an AI drug discovery program in June and OpenAI partnered with Novo Nordisk in April.
Drug discovery startups have raised $23.2 billion in 2026, according to deal-counting platform Dealroom, a record figure.
Isomorphic last raised in May, with a $2.1 billion Series B.Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
AI Trends